1515-89-5

Basic information

• Product Name: 1-Bromo-3-(methoxymethyl)benzene
• Synonyms: 1-Bromo-3-(methoxymethyl)benzene
• CAS NO: 1515-89-5
• Molecular Formula: C₈H₉BrO
• Molecular Weight: 201.07
• Product Categories: Anisoles, Alkyloxy Compounds & Phenylacetates;Bromine Compounds;alkyl bromide
• Mol File: 1515-89-5.mol
• Article Data: 13

Chemical Properties

• Boiling Point: 117-118 °C(Press: 21 Torr)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-Bromo-3-(methoxymethyl)benzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Bromo-3-(methoxymethyl)benzene(1515-89-5)
• EPA Substance Registry System: 1-Bromo-3-(methoxymethyl)benzene(1515-89-5)

Safety Data

• Hazardous Substances Data: 1515-89-5(Hazardous Substances Data)

Usage

General Description

1-Bromo-3-(methoxymethyl)benzene is a chemical compound consisting of a benzene ring with a bromine atom at the 1 position and a methoxymethyl group at the 3 position. 1-Bromo-3-(methoxymethyl)benzene is used as a building block in the synthesis of various pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of dyes and pigments. 1-Bromo-3-(methoxymethyl)benzene is a colorless liquid with a molecular formula of C8H9BrO and a molecular weight of 205.06 g/mol. It is important to handle this compound with caution as it is classified as a hazardous chemical and can cause irritation to the skin, eyes, and respiratory system upon contact or inhalation.

Upstream product

• 823-78-9 meta-bromobenzyl bromide 
• 124-41-4 sodium methylate 
• 67-56-1 methanol 
• 691-38-3 (Z)-4-methyl-2-pentene 
• 15852-73-0 (3-Bromophenyl)methanol 
• 77-78-1 dimethyl sulfate 
• 74-88-4 methyl iodide 
• 3132-99-8 m-bromobenzoic aldehyde 

Downstream Products

• 32194-76-6 3-methoxymethyl-benzoic acid 
• 67638-60-2 3,3'-Bis(methoxymethyl)benzophenone 
• 1515-86-2 (3-Cyanophenyl)methyl methyl ether 
• 253350-30-0 (2S)-3-(3-methoxymethylphenyl)-1-triphenylmethoxypropan-2-ol 
• 256382-23-7 5-thia-16-(3-methoxymethylphenyl)methylPGE₁ 
• 253350-38-8 (3S)-4-(3-methoxymethylphenyl)-1-butyn-3-ol 
• 253350-31-1 (2S)-3-(3-methoxymethylphenyl)propan-1,2-diol 
• 253350-32-2 (2S)-3-(3-methoxymethylphenyl)-1-acetyloxypropan-2-ol 
• 253350-35-5 2-(S)-tetrahydropyranyloxy-3-(3-methoxymethylphenyl)propan-1-al 
• 253350-39-9 3-(S)-t-butyldimethylsilyloxy-4-(3-methoxymethylphenyl)-1-butyne 
• 253350-34-4 2-(S)-tetrahydropyranyloxy-3-(3-methoxymethylphenyl)propan-1-ol 
• 253350-37-7 3-(S)-tetrahydropyranyloxy-4-(3-methoxymethylphenyl)-1-butyne 
• 253350-40-2 3-(S)-tert-butyldimethylsilyloxy-1-iodo-4-(3-methoxymethyl)phenyl-1-butene 
• 253350-36-6 1,1-dibromo-3-(S)-tetrahydropyranyloxy-4-(3-methoxymethylphenyl)-1-butene 

Relevant articles and documents

Cobalt-Catalysed Reductive Etherification Using Phosphine Oxide Promoters under Hydroformylation Conditions

A phosphine-oxide-promoted, cobalt-catalysed reductive etherification using syngas as a reductant is reported. This novel methodology was successfully used to prepare a broad range of unsymmetrical ethers from various aldehydes and alcohols containing diverse functional groups, and was scaled-up to multigram scale under comparably mild conditions. Mechanistic experiments support an acetalization–hydrogenation sequence.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K-ras mutation in a subject in need thereof. The method comprises the steps of: (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) administering to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.

TREATMENT OF CANCERS HAVING K-RAS MUTATIONS

The present invention provides a method of treating a cancer associated with a K- ras mutation in a subject in need thereof. The method comprises the steps of (1) identifying a subject with a cancer associated with a K-ras mutation; and (2) adminsiterign to the subject (i) an inhibitor of PI3 kinase and (ii) an HDAC inhibitor, wherein the PI3 kinase inhibitor and the HDAC inhibitor are administered in amounts which together are therapeutically effective.